Stock Events

Stock Events

Immunovant 

$38.95
58
-$0.76-1.91% 09:16 Today

Statistics

Day High
38.76
Day Low
38.68
52W High
41.23
52W Low
14.32
Volume
18,741
Avg. Volume
-
Mkt Cap
7.95B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.76
-0.7
-0.65
-0.59
Expected EPS
-0.619047
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-505.61MNet Income

Analyst Ratings

44.67Average Price Target
The highest estimate is 62.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMVT. It's not an investment recommendation.
Apple
12
AAPL
Amazon
12
AMZN
Microsoft
11
MSFT
NVIDIA
10
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Argen X
ARGX
Mkt Cap54.85B
argenx competes directly with Immunovant in developing treatments for autoimmune diseases, specifically targeting the FcRn pathway similar to Immunovant's approach.
United Community Banks
UCB
Mkt Cap4.26B
UCB is involved in creating therapies for autoimmune and inflammatory diseases, competing in the same therapeutic areas as Immunovant.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie has a broad portfolio in immunology, including treatments for autoimmune diseases, making it a competitor in the same market as Immunovant.
AMGEN
AMGN
Mkt Cap196.12B
Amgen's focus on novel therapeutics in inflammation and immunology positions it as a competitor to Immunovant in the autoimmune disease space.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline has a diverse immunology pipeline that includes treatments for autoimmune diseases, competing with Immunovant's therapeutic focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals, known for its innovative therapies in immunology, competes with Immunovant in developing treatments for autoimmune diseases.
Novartis
NVS
Mkt Cap293.94B
Novartis has a strong presence in the immunology and dermatology space, making it a competitor to Immunovant in developing autoimmune disease treatments.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb's extensive research in immune system modulation and autoimmune diseases places it as a competitor to Immunovant.

About

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Show more...
CEO
Dr. Frank M. Torti M.B.A., M.D.
Employees
315
Country
United States
ISIN
US45258J1025

Listings

XNAS
US
IMVT
BOATS
BOATS
IMVT.BOATS

0 Comments

Share your thoughts

FAQ

What is Immunovant stock price today?▼
The current price of IMVT is $38.95 USD — it has decreased by -1.91% in the past 24 hours. Watch Immunovant stock price performance more closely on the chart.
What is Immunovant stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immunovant stocks are traded under the ticker IMVT.
Is Immunovant stock price growing?▼
IMVT stock has fallen by -3.47% compared to the previous week, the month change is a +15.11% rise, over the last year Immunovant has showed a +108.18% increase.
What is Immunovant market cap?▼
Today Immunovant has the market capitalization of 7.95B
When is the next Immunovant earnings date?▼
Immunovant is going to release the next earnings report on August 12, 2026.
What were Immunovant earnings last quarter?▼
IMVT earnings for the last quarter are -0.73 USD per share, whereas the estimation was -0.59 USD resulting in a -23.31% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immunovant revenue for the last year?▼
Immunovant revenue for the last year amounts to 0 USD.
What is Immunovant net income for the last year?▼
IMVT net income for the last year is -505.61M USD.
How many employees does Immunovant have?▼
As of July 14, 2026, the company has 315 employees.
In which sector is Immunovant located?▼
Immunovant operates in the Health & Wellness sector.
When did Immunovant complete a stock split?▼
Immunovant has not had any recent stock splits.
Where is Immunovant headquartered?▼
Immunovant is headquartered in Durham, United States.